A Prospective, Multi-Center, Single-Arm Study of the Veriset™ Hemostatic Patch in Controlling Bleeding in Soft Tissue

Inclusion Criteria: * Subject or authorized representative has provided informed consent. * Subject is ≥ 18 years old. * Subject is scheduled for nonemergent surgery where a topical hemostatic agent would be used to control bleeding emanating from a tissue bed following organ dissection or removal or a bleeding tumor tissue bed following resection or dissection, via an open approach. * Subject is willing and able to comply with all aspects of the treatment and evaluation schedule. * Subject has an appropriate Target Bleeding Site (TBS) during the surgical procedure. * TBS bleeding assessment is Type 2 or 3 (refer to table in protocol). Exclusion Criteria: * Subject is pregnant (documented by a positive pregnancy test) or is actively breast-feeding. * Subject has an estimated life expectancy of less than 6 months. * Subject is scheduled for another planned surgery and the subsequent surgery would jeopardize the previous application of study treatment. * Subject is undergoing emergency surgery, i.e. lifesaving procedures performed where patient is in imminent danger of death. * Subject has participated in an investigational drug or device research study within 30 days of enrollment that would interfere with the study. * Subject has an active local infection at the TBS. * The investigator determines that participation in the study may jeopardize teh safety or welfare of the subject.